Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Acerta Pharma BV Clear all
Active, not recruiting Phase 2 Interventional Results available

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724
View directory record Official record
Conditions
Waldenström Macroglobulinemia (WM)
Interventions
Acalabrutinib (ACP-196)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
Santa Barbara, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926
View directory record Official record
Conditions
Mantle Cell Lymphoma (MCL)
Interventions
ACP-196 (acalabrutinib)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
9
States / cities
Tampa, Florida • Chicago, Illinois • Niles, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

NCT04489797
View directory record Official record
Conditions
Infectious Disease
Interventions
Acalabrutinib, Rabeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

NCT04380688
View directory record Official record
Conditions
COVID-19
Interventions
Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
31
States / cities
Anniston, Alabama • Mobile, Alabama • Escondido, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035
View directory record Official record
Conditions
Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
Interventions
Acalabrutinib, Pembrolizumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Fluconazole, Isavuconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03205046
View directory record Official record
Conditions
DLBCL, Richter Syndrome
Interventions
acalabrutinib, vistusertib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 130 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Fairway, Kansas • Bethesda, Maryland • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

NCT04867941
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

NCT02717624
View directory record Official record
Conditions
Mantle Cell Lymphoma (MCL)
Interventions
Acalabrutinib in combination with BR, Acalabrutinib in combination with VR
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Louisville, Kentucky • Ann Arbor, Michigan • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

NCT04901923
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Itraconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1 Interventional

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

NCT02157324
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
acalabrutinib, ACP-319
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Columbus, Ohio • Hermitage, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

NCT04914936
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Calcium carbonate, Omeprazole, Rifampin
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

NCT02328014
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
Interventions
Acalabrutinib, ACP-319
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
7
States / cities
Orange, California • Bethesda, Maryland • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

NCT02337829
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib (Arm A), Acalabrutinib (Arm B)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

NCT02387762
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
acalabrutinib, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

NCT02972840
View directory record Official record
Conditions
Lymphoma, Mantle Cell
Interventions
Acalabrutinib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
65 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
32
States / cities
Tucson, Arizona • Downey, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Results available

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

NCT02211014
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

NCT04905043
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, SmartPill®
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

NCT02537444
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Acalabrutinib, acalabrutinib and pembrolizumab combination
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

NCT02362048
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
ACP-196, ACP-196 in combination with pembrolizumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ACP-196 (acalabrutinib)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Concord, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
acalabrutinib, rituximab (IV), Lenalidomide
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Downey, California • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Ibrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
31
States / cities
Phoenix, Arizona • Anaheim, California • Berkeley, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Results available

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526
View directory record Official record
Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Interventions
Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 23, 2026, 8:53 AM EDT